TransMedics Group, Inc. (TMDX) FY2026 Q2 P&L / Income Statement

TransMedics Group, Inc. (TMDX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

189,948,000 US dollars

Total cost of revenue

76,750,000 US dollars

Gross profit

113,198,000 US dollars

Total operating expenses

89,462,000 US dollars

Income from operations

23,736,000 US dollars

Total other expense, net

negative 4,331,000 US dollars

Income before income taxes

19,405,000 US dollars

Provision for income taxes

4,723,000 US dollars

Net income

14,682,000 US dollars

OCS transplant revenue - UNITED STATES

183,623,000 US dollars

OCS transplant revenue - All Other Countries

5,241,000 US dollars

Undisclosed (calculated)

1,084,000 US dollars

Research, development and clinical trials

31,632,000 US dollars

Selling, general and administrative

57,830,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.